A Screen for Small Molecule Compounds that Inhibit Bacterial Toxins
A Screen for Small Molecule Compounds that Inhibit Bacterial Toxins
批准号:
7304738
负责人:
DAVID B. HASLAM
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-07-01 至 2010-06-30
关键词:
Bacterial ToxinsBindingBiological AssayBiological WarfareCell membraneCell surfaceCellsCholera ToxinCollaborationsComplexCycloheximideCytoplasmDana-Farber Cancer InstituteEndoplasmic ReticulumExposure toFutureGoalsGolgi ApparatusGray unit of radiation doseIn VitroInvestigationLuciferasesMediator of activation proteinPathway interactionsPredispositionProtein BiosynthesisQuality ControlRecyclingReporterResistanceRicinScoreScreening procedureShiga ToxinSiteSpecificityStagingTherapeutic AgentsTherapeutic InterventionToxic effectToxinTranslationsVesiclebasecellular transductioncytotoxicfollow-uphuman diseaseinhibitor/antagonistkillingsmedical schoolsmulticatalytic endopeptidase complexresearch studyretrograde transportsmall moleculetooltrafficking
中文摘要
描述(申请人提供):滋贺毒素(Stx)、霍乱毒素(Ctx)和蓖麻毒素是人类疾病的重要介质,是生物战的潜在制剂。这些毒素遵循复杂的细胞内途径以杀死易感细胞。在与细胞表面分子结合后,这些毒素被内化并以逆行方式通过高尔基体运输到内质网(ER)。从内质网腔,毒素必须进入细胞质,在那里它们进行其细胞毒活性。这一最近发现的途径可能代表了一种回收和细胞质量控制机制,但其特征还很不清楚。由广泛不同来源的毒素利用的逆行转运途径是治疗干预的有吸引力的靶点。然而,逆行交通的机制和所涉及的宿主分子在很大程度上是未知的。我们正在采用一种小分子筛选抑制剂的Stx敏感性作为一种工具,剖析毒素转运途径的组成部分。我们已经开发了几种检测方法来检查抑制性化合物对逆行和前向(分泌)运输的影响。该提案的目标是确定更多的化合物,其中,在多个位点抑制毒素从质膜到内质网腔的运输。我们的测定是基于荧光素酶活性作为毒素抗性的报告基因。用表达荧光素酶的腺病毒构建体转导细胞,所述荧光素酶已被修饰为被蛋白酶体快速降解。暴露于抑制蛋白质合成的Stx导致荧光素酶含量显著减少。抑制Stx转运或活性的化合物导致荧光素酶活性的拯救,并且容易在光度计中检测到。一个counterscreen,包括与放线菌酮,而不是Stx孵育,被纳入排除假阳性命中。筛选和反筛选的效用在ICCB设施中得到验证,其中我们发现z和z'得分> 0.6,并证明了排除对荧光素酶活性具有非特异性影响的化合物的能力。基于我们上一轮的筛选,我们预计从10万个分子的筛选中鉴定出至少50种抑制性化合物。我们将通过确定这些化合物的效力、特异性、毒性、可逆性以及它们对体外毒素运输的影响的初步评估来跟进这些化合物。基于该分析的结果,将优先考虑将化合物纳入将鉴定毒素抑制位点和抑制性化合物的细胞内靶标的研究中。这里提出的调查将确定有效的和具体的毒素贩运抑制剂。这些化合物将被用作探针,以确定运输途径和参与毒素运输的各个阶段的宿主分子。在未来的实验中,这些化合物中的一些将被优化用于潜在的治疗剂。滋贺毒素、霍乱毒素和蓖麻毒素是人类疾病的重要病原体,被认为是生物战的潜在病原体。这些毒素和其他毒素遵循复杂的细胞内途径,以杀死易感细胞。该转运途径是治疗干预的有吸引力的靶点。我们正在采用小分子筛选滋贺毒素作用的抑制剂。将检测具有抗滋贺毒素活性的化合物抑制蓖麻毒素和霍乱毒素的能力。然后将对化合物的效力、毒性、可逆性和作用机制进行表征。所得化合物将是剖析毒素和囊泡运输途径的有价值的工具。在最终的目标,抑制分子的宿主靶点将被确定。从长远来看,抑制毒素运输并在体外显示最小毒性的化合物将被探索为潜在的治疗剂。
英文摘要
DESCRIPTION (provided by applicant): Shiga toxin (Stx), cholera toxin (Ctx) and ricin are important mediators of human disease and are potential agents of biowarfare. These toxins follow a complex intracellular pathway in order to kill susceptible cells. After binding to cell surface molecules, these toxins are internalized and trafficked in retrograde fashion through the Golgi to the endoplasmic reticulum (ER). From the ER lumen, the toxins must gain access to the cytoplasm, where they carry out their cytotoxic activities. This recently discovered pathway likely represents a recycling and cellular quality control mechanism that has as yet been poorly characterized. The retrograde transport pathway, exploited by toxins of widely different origin, is an attractive target for therapeutic intervention. However, the mechanisms of retrograde traffic and the host molecules involved are largely unknown. We are employing a small molecule screen for inhibitors of Stx susceptibility as a tool to dissect the components of toxin transport pathways. We have developed several assays to examine the effects of inhibitory compounds on retrograde and forward (secretory) transport. The goal of this proposal is to identify several more compounds that, among them, inhibit toxins at multiple sites in their transport from plasma membrane to ER lumen. Our assay is based on luciferase activity as a reporter for toxin resistance. Cells are transduced with an adenoviral construct expressing luciferase that has been modified to be degraded rapidly by the proteasome. Exposure to Stx, which inhibits protein synthesis, results in markedly diminished luciferase content. Compounds that inhibit Stx transport or activity result in a rescue of the luciferase activity and are readily detected in a luminometer. A counterscreen, consisting of incubation with cycloheximide rather than Stx, was incorporated to exclude false-positive hits. The utility of the screen and counterscreen were validated at the ICCB facility, where we found z and z' scores to be > 0.6 and demonstrated the ability to exclude compounds with nonspecific effects on luciferase activity. Based on our previous round of screening we anticipate identifying at least 50 inhibitory compounds from a screen of 100,000 molecules. We will follow up on these compounds by determining their potency, specificity, toxicity, reversibility, and a preliminary assessment of their effect on toxin trafficking in vitro. Based on the results of this analysis, the compounds will be prioritized for their inclusion into studies that will identify the site of toxin inhibition and the intracellular targets of inhibitory compounds. Investigations proposed here will identify potent and specific inhibitors of toxin trafficking. These compounds will be used as probes to identify trafficking pathways and host molecules involved in various stages of toxin transport. In future experiments, some of these compounds will be optimized for potential use as therapeutic agents. Shiga toxin, cholera toxin and ricin are important agents of human disease and are recognized as potential agents of biowarfare. These and other toxins follow a complex intracellular pathway in order to kill susceptible cells. This transport pathway is an attractive target for therapeutic intervention. We are employing a small molecule screen for inhibitors of shiga toxin action. Compounds with activity against shiga toxin will be examined for their ability to inhibit ricin and cholera toxin. The compounds will then be characterized with respect to their potency, toxicity, reversibility, and mechanism of action. The resulting compounds will be valuable tools to dissect toxin and vesicle trafficking pathways. In the final aim, the host targets of inhibitory molecules will be identified. Over the long term, compounds that inhibit toxin trafficking and display minimal toxicity in vitro will be explored as potential therapeutic agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of MK2 kinase in toxin-associated disease
-
批准号:7945859
-
项目类别:
-
资助金额:$15.19万
-
财政年份:2009
-
负责人:DAVID B. HASLAM
-
依托单位:
AN HTS ASSAY FOR INHIBITORS OF C. DIFFICLE TOXINS
-
批准号:8586690
-
项目类别:
-
资助金额:$3.8万
-
财政年份:2009
-
负责人:DAVID B. HASLAM
-
依托单位:
Discovery of Novel Therapeutics Against Shiga and Ricin Toxins
-
批准号:7641861
-
项目类别:
-
资助金额:$11.57万
-
财政年份:2008
-
负责人:DAVID B. HASLAM
-
依托单位:
A SCREEN FOR SMALL MOLECULE INHIBITORS OF SHIGA TOXIN AND RICIN ACTIVITY
-
批准号:7850030
-
项目类别:
-
资助金额:$0.81万
-
财政年份:2008
-
负责人:DAVID B. HASLAM
-
依托单位:
Role of ER-Localized Chaperones in Toxin Pathogenesis
-
批准号:6696888
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2002
-
负责人:DAVID B. HASLAM
-
依托单位:
Role of ER-Localized Chaperones in Toxin Pathogenesis
-
批准号:7007298
-
项目类别:
-
资助金额:$18.68万
-
财政年份:2002
-
负责人:DAVID B. HASLAM
-
依托单位:
ER-Localized Chaperones in Toxin Pathogenesis
-
批准号:6542592
-
项目类别:
-
资助金额:$9.56万
-
财政年份:2002
-
负责人:DAVID B. HASLAM
-
依托单位:
Role of ER-Localized Chaperones in Toxin Pathogenesis
-
批准号:6843730
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2002
-
负责人:DAVID B. HASLAM
-
依托单位:
Role of ER-Localized Chaperones in Toxin Pathogenesis
-
批准号:6642011
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2002
-
负责人:DAVID B. HASLAM
-
依托单位:
GLYCOLIPIDS AND HEMOLYTIC UREMIC SYNDROME
-
批准号:6373801
-
项目类别:
-
资助金额:$11.0万
-
财政年份:1998
-
负责人:DAVID B. HASLAM
-
依托单位:
GLYCOLIPIDS AND HEMOLYTIC UREMIC SYNDROME
-
批准号:2887701
-
项目类别:
-
资助金额:$11.65万
-
财政年份:1998
-
负责人:DAVID B. HASLAM
-
依托单位:
GLYCOLIPIDS AND HEMOLYTIC UREMIC SYNDROME
-
批准号:6170643
-
项目类别:
-
资助金额:$10.92万
-
财政年份:1998
-
负责人:DAVID B. HASLAM
-
依托单位:
GLYCOLIPIDS AND HEMOLYTIC UREMIC SYNDROME
-
批准号:6510811
-
项目类别:
-
资助金额:$11.02万
-
财政年份:1998
-
负责人:DAVID B. HASLAM
-
依托单位:
GLYCOLIPIDS AND HEMOLYTIC UREMIC SYNDROME
-
批准号:2591934
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1998
-
负责人:DAVID B. HASLAM
-
依托单位:
REGULATION OF GLOBOPENTOSYLCERAMIDE EXPRESSION
-
批准号:2207194
-
项目类别:
-
资助金额:$3.5万
-
财政年份:1995
-
负责人:DAVID B. HASLAM
-
依托单位:
REGULATION OF GLOBOPENTOSYLCERAMIDE EXPRESSION
-
批准号:2207195
-
项目类别:
-
资助金额:$3.54万
-
财政年份:1995
-
负责人:DAVID B. HASLAM
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: